Corporate Governance

Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business development, commercialization, strategic planning, and general management. Since 2011, he has served as the President and Chief Executive Officer of Nasdaq-listed biopharmaceutical company, Genocea Biosciences, Inc. In that role, among other accomplishments, he executed Genocea’s successful strategic pivot from infectious disease to immuno-oncology. Prior to joining Genocea, Mr. Clark was Chief Business Officer at Vanda Pharmaceuticals Inc., a company he co-founded in 2004. There, he played central roles in completing the company’s 2006 Nasdaq initial public offering and its 2009 out-licensing deal with Novartis Pharma AG, from which Vanda received an upfront payment of $200 million, plus contingent additional future milestone payments totaling up to $265 million. Previously, he was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies. Earlier in his career, he spent 10 years at SmithKline Beecham Corporation (now part of GlaxoSmithKline plc) in a variety of business development roles. Mr. Clark holds an MBA from The Wharton School at the University of Pennsylvania and a BA from Harvard University.

Prior to becoming CEO for iBio in March 2020, Mr. Isett played an integral part in reshaping the Company’s strategy and operations in his role as Board Member and Strategic Advisor since April 2019. He was able to contribute his deep management and strategic insights via the consulting firm he founded in 2015, i.e. Advising, LLC, which supported Fortune 500s, institutional investors, biotechs and non-profits alike with M&A, turnarounds, and more. 

Previously, he ran business units for GE, Lonza, and BD, ranging in size from start-up to a half billion in revenues. Notably, he founded BD Advanced Bioprocessing (which sold to ThermoFisher in 2018 for $477M), and Commence Bio, Inc. a cellular immunotherapy company. Mr. Isett received his B.Sc. degree with Honors in Biological Sciences from Drexel University.

Dr. Linda Armstrong has more than 20 years of experience in biopharmaceutical research.  She currently leads the Global Respiratory Development Unit at Novartis. She has served in a range of executive roles across R&D disciplines including Clinical Development, Patient Safety and Medical Affairs, supporting the development of small molecules, biologics and cell and gene therapies. Prior to her current role, she held management positions at the Schering-Plough Research Institute and Pfizer, Inc. Dr. Armstrong received her medical degree from Yale University School of Medicine and her Bachelor’s Degree from Harvard University. She is a trained Pulmonologist and was on the faculty at New York University School of Medicine prior to joining industry.

Since February 2014, Glenn Chang serves as Finance Officer of Singer Vehicle Design, a private company in the business of automotive design and restoration. Mr. Chang served as the Chief Financial Officer of Alma Bank, a New York headquartered bank with over $900 million of assets and 13 branches in the New York City Metropolitan area from late 2012 to February 2014. Before joining Alma, from 1999 to 2012, Mr. Chang served as a founder, Director, Chief Financial Officer and consultant to First American International Bank which was the largest locally owned Chinese American Bank in New York City. Prior to that he spent 20 years at Citibank, N.A as Vice President. Mr. Chang is a retired Certified Public Accountant. Mr. Chang's extensive executive and financial leadership in his current and former positions and his training and experience as a Certified Public Accountant adds vital expertise to our board of directors and our Audit Committee in the form of financial understanding, business perspective and audit expertise. Mr. Chang is qualified as an Audit Committee Financial Expert as defined in Regulation S-K Item 407(d)(5)(ii).

General (Ret.) James T. Hill was the Commander of the 4-Star United States Southern Command, reporting directly to the President and Secretary of Defense at the time of his retirement from active duty. As such, he led all U.S. military forces and operations in Central America, South America and the Caribbean, worked directly with U.S. Ambassadors, foreign heads of state, key Washington decision-makers, foreign senior military and civilian leaders, developing and executing United States policy. His responsibilities included management, development and execution of plans and policy within the organization including programming, communications, manpower, operations, logistics and intelligence. General Hill's deep experience managing and leading large diverse organizations through periods of great change is a key resource.

Dr. Kropotova is a biopharmaceutical executive with 20+ years of global R&D experience in all phases of global clinical development, translational medicine, and medical affairs. Currently, she is Executive Vice President & Chief Medical Officer at SAb Biotherapeutics, leading the strategy, direction, and execution of the company’s portfolio of innovative polyclonal antibody assets. Prior to joining SAb Biotherapeutics, Dr. Kropotova was Therapeutic Area Head of Global Specialty R&D at Teva Pharmaceuticals, leading innovative drug development across a broad portfolio of immunology and immuno-oncology assets spanning from pre-IND to BLA/NDA filing of biologics and complex drug-device combination products. Dr. Kropotova also served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D Clinical Development; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. She also served in various roles at Wyeth and Pfizer. Dr. Kropotova received her MBA from Ohio University Graduate School of Business, Athens, Ohio; and her M.D. in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia.

In an executive leadership career spanning more than 20 years, Mr. Schimmelpennink has applied his strategic and functional expertise across corporate development, commercial operations, manufacturing, and R&D to help build and scale a number of global public and private biopharmaceutical businesses. He currently serves as President and CEO of LENZ Therapeutics, a biopharmaceutical company with a lead late clinical-stage program that represents a potential best-in-class therapy for presbyopia. Previously, he served as CEO of Pfenex Inc., a NYSEA-listed company which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million (including contingent value rights) in October 2020. Previously, Mr. Schimmelpennink served as CEO of Alvotech Ehf, a global biopharmaceutical company focused on becoming a leader in the biosimilar monoclonal antibody market. Prior to joining Alvotech, he held variety of progressive roles with Pfizer Inc., Hospira, Inc., Synthon BV and Numico NV. Mr. Schimmelpennik also serves on the board of directors of Pipeline Therapeutics, Inc. Mr. Schimmelpennink holds a Masters in Bioprocess Engineering from the Wageningen University in the Netherlands.

Gary Sender is currently President of Sender Consulting LLC and previously served as the Chief Financial Officer of Nabriva Therapeutics plc from 2016 until his retirement in 2021. Nabriva is a Nasdaq-listed biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Prior to joining Nabriva, he served as CFO and Executive Vice President at Synergy Pharmaceuticals from 2015 to 2016. From 2009 until 2015, Mr. Sender served as Senior Vice President, Finance at Shire Plc., supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Mr. Sender also serves on the board of directors of Schrodinger Inc., Harmony Biosciences Holdings, Inc. and Elucida Oncology. He is the Chairman of the three Board’s Audit Committees. Mr. Sender received his B.S. from Boston University and an M.B.A from Carnegie‑Mellon University.